CRISPR Therapeutics AG (NASDAQ:CRSP) shares, rose in value, with the stock price down by -0.75% to the previous day’s close as strong demand from buyers drove the stock to $38.88.
Actively observing the price movement in the recent trading, the stock is buoying the session at $39.18, falling within a range of $38.6 and $39.28. The value of beta (5-year monthly) is 1.762. Referring to stock’s 52-week performance, its high was $71.54, and the low was $36.52. On the whole, CRSP has fluctuated by -12.42% over the past month.
With the market capitalization of CRISPR Therapeutics AG currently standing at about $3.34 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-10.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 6.36M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRSP’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CRSP currently trading nearly -8.00% and -9.50% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.48, while the 7-day volatility ratio is showing 3.48% which for the 30-day chart, stands at 5.38%. Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 1.80, and its average true range (ATR) is 2.17.
A comparison of CRISPR Therapeutics AG (CRSP) with its peers suggests the former has fared considerably weaker in the market. CRSP showed an intraday change of -0.75% in today’s session so far, and over the past year, it shrunk by -45.30%%.
Data on historical trading for CRISPR Therapeutics AG (NASDAQ:CRSP) indicates that the trading volumes over the past 10 days have averaged 1.49 and over the past 3 months, they’ve averaged 2.11 million. According to company’s latest data on outstanding shares, there are 85.74 million shares outstanding.
Nearly 4.30% of CRISPR Therapeutics AG’s shares belong to company insiders and institutional investors own 69.36% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 20.31 million shares as on 2025-03-14, resulting in a short ratio of 8.11. According to the data, the short interest in CRISPR Therapeutics AG (CRSP) stood at 2682.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 20.41 million. The stock has fallen by -1.21% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRSP stock heading into the next quarter.
